Premedication to Prevent Contrast Reactions: Myths and Pearls in the ED

Authors: Kevin Molyneux, MD, MPH (APD/Assistant Professor of EM, Mount Sinai Morningside-West); Jenny Beck-Esmay, MD (APD/Assistant Professor of EM, Mount Sinai Morningside-West) // Reviewed by: Brit Long, MD (@long_brit)

Case

A 47-year-old female is brought to the Emergency Department for sudden-onset epigastric pain radiating to the back. She reports that the pain started approximately 45 minutes prior to arrival.

Vitals are notable for a blood pressure of 215/112, HR of 110, temperature of 37.6C, RR 14, and 97% on RA. She appears uncomfortable. You order a computed tomography (CT) angiogram to evaluate the patient’s aorta. She has an allergy to “iodine” in her chart marked as “high risk.” The patient states that she doesn’t recall what the reaction was but that she was told to never have intravenous contrast in the past. Radiology wants to know if you will be premedicating the patient prior to CT.

Will you premedicate the patient for a contrast reaction? If the patient had a less severe presentation, would premedication help prevent an adverse reaction?

Background

Over 85 million CT scans are done annually in the U.S., about half of which use intravenous (IV) iodinated contrast material (ICM) (Yeh et al, 2016). ICM is needed for accurate diagnosis of various pathologies, especially in the cases of abdominal pain, infections, and vascular pathology.

Patients who report being allergic to ICM are less likely to undergo ICM-enhanced CT imaging than nonallergic, which may lead to suboptimal imaging (Berlyand et al, 2022). Many practices use a premedication regiment, typically an antihistamine and steroid, followed by a waiting periods before ICM can be given, which more than doubles the time to imaging start compared to patients who do not undergo premedication (Berlyand et al, 2022). Such delays are linked to higher mortality, longer time to treatment of pain, and longer time to diagnosis of time-sensitive diagnoses, and higher evidence that the patient leaves the ED against medical advice (Molyneux 2026). However, the evidence that premedication prevents significant reactions is sparse.

Overview of ICM Agents

In the early days of contrast-enhanced CT, there were high rates of adverse reactions. The high osmolality contrast used was nephrotoxic, and could induce vasodilation, bradycardia, and pulmonary hypertension (Lusic). To limit this, newer ICM agents were made to be low osmolality, which decreased the rate of adverse reactions (Lusic). However, these had a high viscosity, making it hard to quickly administer contrast when needed for studies such as CT angiography, so low-viscosity formulations were made (Lusic). Modern ICM agents are low-toxicity, low-viscosity, and low-osmolality, with significantly lower rates of adverse events (Molyneux). In the 20 interceding years, no substantively new agents have been approved for clinical use (Molyneux). A 1990 study of contrast agents found high-osmolality had an adverse reaction rate of 12.66% and severe reactions in 0.22%, while low-osmolality had an overall rate of 3.13% and severe reactions in 0.04% (Katayama)

ICM by Osmolality (Molyneux)

Pathophysiology

The pathophysiology of ICM-reactions is not well understood. No definite antibodies have been found against ICM, and the role of IgE is debated, though the reaction mimics an allergic reaction and the recommended treatment is the same (Gottumukkala).

Adverse Reactions

Common Immediate Reactions (Molyneux)

With low-osmolality contrast, 0.2% – 0.5% of injections have a mild reaction, 0.04% to 0.1% have a moderate reaction, 0.005% to 0.06% severe, and fatalities occur in 0.0006% of injections (Wang 2008, Torres). Patients may also have reactions unrelated to the ICM like panic attacks or vasovagal responses (Kang).

Delayed reactions occur in 1-3% of ICM administrations, and while most occur 6-12 hours after exposure, they can be delayed up to a week (Asch, Beaty). Most reactions are uncomplicated maculopapular rashes (Asch).

Treatment of Common Contrast Reactions (Molyneux)

Premedication Protocols

Premedication with steroids emerged in the 1980s to prevent reactions to the high-osmolality contrast. A 1987 study found that 32mg methylprednisolone given 12 and 2 hours before high-osmolality ICM administration decreased rates of reactions by 31%, which brought the reaction rate near that of the “new” expensive low-osmolality ICM which did not require premedication (Davenport, Lasser). A 2-hour only premedication protocol had no effect.

For emergent studies, the American College of Radiology (ACR) recommends a protocol of methylprednisolone 40mg IV or hydrocortisone 200mg IV every 4-5 hours until ICM administration, with diphenhydramine 50mg IV 1 hour before the ICM administration (Wang 2025).

Evidence for Premedication

Methylprednisolone given 6-24 hours prior to low-osmolality ICM reduces the mild reaction rate from 1.9% to 0.2% without any effect on moderate or severe reactions (Davenport 2017, Schrijvers). The risk ratio for premedication to prevent an anaphylaxis-like reaction is 1.07 with a 95% confidence interval 0.67-1.71 (Shaker).

Protocols for rapid premedication are largely based on a 1986 case series which demonstrated that zero of nine high-risk patients given 200mg hydrocortisone every 4 hours prior to ICM exposure and benadryl 1 hour prior developed an adverse reaction (Molyneux). A 5 hour intravenous corticosteroid premedication protocol was found to be noninferior to the traditional 13-hour oral steroid premedication to prevent overall adverse reactions (Molyneux). The ACR notes that there is no evidence to support any protocol of 2 hours or less (ACR).

In patients with previous reactions, 10% will have a breakthrough even with premedication (Freed). 81% of these reactions are of a similar severity to the initial reaction, and 8% are more severe (Davenport 2009). Changing the ICM to a different agent, where possible, can reduce the rates of reaction by approximately 61-67%, more effectively than premedication (Park;Umakoshi;McDonald). In fact, a 2025 joint article by the ACR and th American Academy of Allergy, Asthma, & Immunology recommends against premedication patients with a history of mild immediate ICM reaction and recommends changing to a different ICM agent if the inciting agent is known and such a change is possible (Wang 2025).

Harm from Premedication

ICM premedication delays patients’ imaging and diagnosis. There is a limited benefit in preventing mild, self-resolving contrast reactions, but no clearly demonstrated benefit to prevent severe reactions from contrast premedication. Regardless of previous reactions, imaging to evaluate life-threatening pathology such as aortic dissection should never be delayed to premedicate a patient.

Premedication agents are not entirely benign. Antihistamines can lead to drowsiness and impaired vehicle operation after administration (Molyneux). Corticosteroids are associated with longer hospital stays, increased costs, and worse patient outcomes (Davenport 2015).

The number needed to treat (NNT) for steroid premedication to prevent any one reaction is 69. To prevent a severe reaction, the NNT is 569, and for a fatal reaction, it is 56,900 (Molyneux).

Among inpatients treated with contrast premedication, there was a 25 hour longer time to CT, which was calculated to have an excess cost of $159,131 and an increase in hospital-acquired infections by 0.7 for each prevented ICM reaction of any type (Davenport 2015). For each prevented reaction-related death, premedication cost $131,211,400 in increased stays and was associated with 32 more deaths related to hospital-acquired infections (Davenport 2015).

Premedication can also lead to a false sense of security among physicians. Breakthrough reactions do still occur even with premedication. Thus, the EP should be familiar with the nearest resuscitation equipment to the CT scanner, and be ready to resuscitate patients with significant reactions to contrast.

References

1. American College of Radiology. ACR Manual on Contrast Media. 2025.

2. Asch D, Callahan MJ, Thomas KL, et al. Management of severe allergic-like contrast media reactions: pitfalls and strategies, from the AJR special series on contrast media. AJR 2023;223(2):e2330044.

3. Beaty AD, Lieberman PL, Slavin RG. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med 2008;121(2):158, e1-e4.

4. Berlyand Y, Fraga JA, Succi MD, et al. Impact of iodinated contrast allergies on emergency department operations. Am J Emerg Med 2022;61:127–30.

5. Davenport MD, Cohan RH, Caoili EM, et al. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 2009;253(2):372–9.

6. Davenport MS, Cohan RH. The evidence for and against corticosteroid prophylaxis in At-Risk patients. Radiol Clin North Am 2017;55(2):413–21.

7. Davenport MS, Mervak BM, Ellis JH, et al. Indirect Cost and Harm Attributable to Oral 13-Hour Inpatient Corticosteroid Prophylaxis before Contrast-enhanced CT. Radiology. 2015;279(2).

8. Davenport MS, Weinstein S. (Still) wondering if we should stop giving steroid preps. Radiology 2021;301(1):141–3.

9. Freed KS, Leder RA, Alexander C, et al. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR 2001;176(6):1389–92.

10. Gottumukkala RV, Glover M, Yun BJ, et al. Allergic-like contrast reactions in the ED: incidence, management, and impact on patient disposition. Am J Emerg Med 2018;36(5):825–8.

11. Kang HR, Jeong J, Brockow K. Diagnosis and prevention of hypersensitivity reactions to iodinated contrast media. Allergy Asthma Immunol Res 2022;14(4):348–60.

12. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese committee on the safety of contrast media. Radiology 1990;175(3):621–8.

13. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. NEJM 1987;314(14):845–9.

14. Lusic H, Grinstaff MW. X-Ray computed tomography contrast agents. Chem Rev 2012;113(3):1641–66.

15. McDonald JS, Larson NB, Kolbe AB, et al. Prevention of Allergic-like Reactions at Repeat CT: Steroid Pretreatment versus Contrast Material Substitution. Radiology. 2021;301(1):133-140.

16. Molyneux K, Beck-Esmay J. Myth: Pretreatment Prevents Intravenous Contrast Reactions in the Emergency Department. Emerg Med Clin N Am. 2026;44:533-545.

17. Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study. Eur Radiol. 2017;27(7):2886-2893.

18. Schrijvers R, Demoly P, Chiriac AM. Premedication for iodinated contrast media induced immediate hypersensitivity reactions. Curr Treat Options Allergy 2019;6:538–53.

19. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. J Allergy Clin Immunol 2020;145(4):1082-1123.

20. Torres MJ, Trautmann A, Bo ¨ hm I, et al. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Allergy 2021;76:1325–39.

21. Umakoshi H, Nihashi T, Takada A, et al. Iodinated Contrast Media Substitution to Prevent Recurrent Hypersensitivity Reactions: A Systematic Review and Meta-Analysis. Radiology. 2022;305(2):341-349.

22. Wang CL, Cohan RH, Ellis JH, et al. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR 2008;191:409–15.

23. Wang CL, Ramsey A, Lang D, et al. Management and prevention of hypersensitivity reactions to radiocontrast media: a consensus statement from the American college of radiology and the American Academy of Allergy. Asthma, & Immunology. J Allergy Clin Immunol Pract 2025;13(5):1029–47.

24. Yeh BM, FitzGerald PF, Edic PM, et al. Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies. Adv Drug Deliv Rev 2016;113:201–22.